Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
$144.31M
14 trades · 6 insiders
Net · 90d
$-144.31M
Insiders on file
24
Daily buy vs sell · 90 days
■ Open-market buys (P) ■ Open-market sales (S) · daily dollar value by transaction date
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Bhatt Elizabeth | President and COO | 28 | $0 | $2.70M | 2026-10-15 |
| Patni Rajiv | Chief Medical Officer | 2 | $0 | $0 | 2026-09-08 |
| Long Daniel D. | SVP, Drug Discovery | 31 | $0 | $1.19M | 2026-09-01 |
| Third Rock Ventures GP VI, L.P. | 10% Owner | 2 | $0 | $7.40M | 2026-08-12 |
| Third Rock Ventures V, L.P. | 10% Owner | 2 | $0 | $7.40M | 2026-08-12 |
| Shah Rajeev M. | Director, 10% Owner | 8 | $75.06M | $63.45M | 2026-08-12 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | 2 | $0 | $63.45M | 2026-08-12 |
| Shaikhly Samira | Chief People Officer | 28 | $0 | $2.80M | 2026-06-29 |
| Bassan Abraham | Director | 2 | $0 | $0 | 2026-06-26 |
| Simson Jake | Director | 2 | $0 | $0 | 2026-06-26 |
| Coulie Bernard | Director | 2 | $0 | $0 | 2026-06-26 |
| Ezekowitz Alan | Director | 6 | $608.2K | $0 | 2026-06-26 |
| Gottesdiener Keith Michael | Director | 2 | $0 | $0 | 2026-06-26 |
| Tong Jeffrey K | Director | 2 | $0 | $0 | 2026-06-26 |
| Kolchinsky Peter | Director, 10% Owner | 1 | $0 | $0 | 2026-06-26 |
| Sharp Shalini | Director | 2 | $0 | $0 | 2026-06-26 |
| Finer Jeffrey | Chief Executive Officer | 9 | $97.0K | $0 | 2026-02-06 |
| Klein Uwe | SVP, Biological Sciences | 8 | $0 | $0 | 2026-02-06 |
| Kim Jae B. | Chief Medical Officer | 2 | $0 | $0 | 2026-02-06 |
| Wilson Mark Andrew | Chief Legal Officer | 1 | $0 | $0 | 2026-02-06 |
| Labrucherie Gil M | Chief Financial Officer | 8 | $229.2K | $0 | 2026-02-06 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 1 | $0 | $0 | 2025-06-17 |
| Third Rock Ventures GP V, LP | 10% Owner | 3 | $6.28M | $0 | 2025-02-24 |
| TRV GP V, LLC | 10% Owner | 6 | $11.70M | $0 | 2024-10-28 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-10-15 | 2026-10-19 | 4,000 | — | $0 | 58,230 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-10-15 | 2026-10-19 | 2,906 | $37.61 | $109.3K | 174,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-10-15 | 2026-10-19 | 1,094 | $36.87 | $40.3K | 177,115 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-10-15 | 2026-10-19 | 4,000 | $6.81 | $27.2K | 178,209 | SEC↗ |
| Patni Rajiv | Chief Medical Officer | A Award deriv | 2026-09-08 | 2026-09-10 | 275,000 | — | $0 | 275,000 | SEC↗ |
| Patni Rajiv | Chief Medical Officer | A Award deriv | 2026-09-08 | 2026-09-10 | 275,000 | — | $0 | 275,000 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-09-01 | 2026-09-03 | 3,333 | — | $0 | 9,085 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-09-01 | 2026-09-03 | 3,333 | $37.83 | $126.1K | 96,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-09-01 | 2026-09-03 | 3,333 | $2.76 | $9.2K | 99,745 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-09-01 | 2026-09-03 | 3,333 | — | $0 | 9,085 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-09-01 | 2026-09-03 | 3,333 | $37.83 | $126.1K | 96,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-09-01 | 2026-09-03 | 3,333 | $2.76 | $9.2K | 99,745 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 746,500 | $42.50 | $31.73M | 725,443 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 746,500 | $42.50 | $31.73M | 4,777,415 | SEC↗ |
| Third Rock Ventures GP VI, L.P | 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 147,059 | $50.27 | $7.39M | 6,068,532 | SEC↗ |
| Third Rock Ventures GP VI, L.P | 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 141 | $51.08 | $7.2K | 6,068,391 | SEC↗ |
| Third Rock Ventures V, L.P. | 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 141 | $51.08 | $7.2K | 6,068,391 | SEC↗ |
| Third Rock Ventures V, L.P. | 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 147,059 | $50.27 | $7.39M | 6,068,532 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 746,500 | $42.50 | $31.73M | 725,443 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | S Sale | 2026-08-12 | 2026-08-14 | 746,500 | $42.50 | $31.73M | 4,777,415 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-08-11 | 2026-08-13 | 18,681 | — | $0 | 62,230 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-08-11 | 2026-08-13 | 6,319 | — | $0 | 82,332 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-08-11 | 2026-08-13 | 6,319 | $2.76 | $17.4K | 199,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-08-11 | 2026-08-13 | 25,000 | $44.00 | $1.10M | 174,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-08-11 | 2026-08-13 | 18,681 | $6.81 | $127.2K | 192,890 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-08-11 | 2026-08-13 | 6,319 | — | $0 | 82,332 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-08-11 | 2026-08-13 | 18,681 | — | $0 | 62,230 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-08-11 | 2026-08-13 | 25,000 | $44.00 | $1.10M | 174,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-08-11 | 2026-08-13 | 6,319 | $2.76 | $17.4K | 199,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-08-11 | 2026-08-13 | 18,681 | $6.81 | $127.2K | 192,890 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-08-03 | 2026-08-05 | 1,816 | — | $0 | 5,227 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-08-03 | 2026-08-05 | 1,518 | — | $0 | 12,418 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-08-03 | 2026-08-05 | 1,518 | $2.76 | $4.2K | 99,746 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-08-03 | 2026-08-05 | 1,816 | $2.76 | $5.0K | 98,228 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-08-03 | 2026-08-05 | 1,000 | $33.98 | $34.0K | 98,746 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-08-03 | 2026-08-05 | 2,334 | $34.68 | $80.9K | 96,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-08-03 | 2026-08-05 | 1,518 | — | $0 | 12,418 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-08-03 | 2026-08-05 | 1,816 | — | $0 | 5,227 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-08-03 | 2026-08-05 | 2,334 | $34.68 | $80.9K | 96,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-08-03 | 2026-08-05 | 1,000 | $33.98 | $34.0K | 98,746 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-08-03 | 2026-08-05 | 1,518 | $2.76 | $4.2K | 99,746 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-08-03 | 2026-08-05 | 1,816 | $2.76 | $5.0K | 98,228 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-07-15 | 2026-07-17 | 4,000 | — | $0 | 80,911 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-07-15 | 2026-07-17 | 4,000 | $6.81 | $27.2K | 178,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-07-15 | 2026-07-17 | 4,000 | $33.99 | $136.0K | 174,209 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-07-01 | 2026-07-02 | 3,333 | — | $0 | 7,043 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-07-01 | 2026-07-02 | 2,100 | $34.10 | $71.6K | 97,645 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-07-01 | 2026-07-02 | 3,333 | $2.76 | $9.2K | 99,745 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-07-01 | 2026-07-02 | 1,233 | $34.81 | $42.9K | 96,412 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-06-29 | 2026-06-30 | 2,178 | — | $0 | 20,865 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-06-29 | 2026-06-30 | 2,178 | $35.18 | $76.6K | 793 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-06-29 | 2026-06-30 | 2,178 | $6.81 | $14.8K | 2,971 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Simson Jake | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Gottesdiener Keith Michael | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 11,260 | — | $0 | 11,260 | SEC↗ |
| Tong Jeffrey K | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Coulie Bernard | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Sharp Shalini | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Bassan Abraham | Director | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Kolchinsky Peter | Director, 10% Owner | A Award deriv | 2026-06-26 | 2026-06-30 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-06-22 | 2026-06-24 | 4,471 | — | $0 | 25,529 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise deriv | 2026-06-22 | 2026-06-24 | 10,529 | — | $0 | 10,376 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-06-22 | 2026-06-24 | 4,471 | $11.70 | $52.3K | 111,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-06-22 | 2026-06-24 | 8,000 | $35.10 | $280.8K | 103,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2026-06-22 | 2026-06-24 | 7,000 | $35.97 | $251.8K | 96,412 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | M Exercise | 2026-06-22 | 2026-06-24 | 10,529 | $2.76 | $29.1K | 106,941 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-06-12 | 2026-06-16 | 6,250 | — | $0 | 23,750 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-06-12 | 2026-06-16 | 6,250 | $35.08 | $219.3K | 793 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-06-12 | 2026-06-16 | 6,250 | $11.70 | $73.1K | 7,043 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-06-01 | 2026-06-03 | 4,355 | — | $0 | 11,614 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-06-01 | 2026-06-03 | 637 | — | $0 | 4,464 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-06-01 | 2026-06-03 | 943 | — | $0 | 2,517 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-06-01 | 2026-06-03 | 1,346 | $28.79 | $38.8K | 3,682 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-06-01 | 2026-06-03 | 4,355 | $1.55 | $6.8K | 5,148 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-06-01 | 2026-06-03 | 943 | $2.76 | $2.6K | 6,091 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-06-01 | 2026-06-03 | 637 | $2.76 | $1.8K | 6,728 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-06-01 | 2026-06-03 | 2,889 | $29.66 | $85.7K | 793 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-06-01 | 2026-06-03 | 1,700 | $27.78 | $47.2K | 5,028 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-05-26 | 2026-05-28 | 11,798 | — | $0 | 23,043 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-05-26 | 2026-05-28 | 11,798 | $6.81 | $80.3K | 12,591 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-05-26 | 2026-05-28 | 11,798 | $30.06 | $354.6K | 793 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-04-15 | 2026-04-17 | 4,000 | — | $0 | 84,911 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-04-15 | 2026-04-17 | 1,101 | $25.24 | $27.8K | 174,535 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-04-15 | 2026-04-17 | 4,000 | $6.81 | $27.2K | 178,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-04-15 | 2026-04-17 | 326 | $25.86 | $8.4K | 174,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-04-15 | 2026-04-17 | 2,573 | $23.76 | $61.1K | 175,636 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-03-02 | 2026-03-04 | 11,638 | — | $0 | 3,460 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-03-02 | 2026-03-04 | 5,101 | — | $0 | 5,101 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise deriv | 2026-03-02 | 2026-03-04 | 53,714 | — | $0 | 15,969 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-03-02 | 2026-03-04 | 53,714 | $1.55 | $83.3K | 54,507 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-03-02 | 2026-03-04 | 11,638 | $2.76 | $32.1K | 66,145 | SEC↗ |
| Shaikhly Samira | Chief People Officer | M Exercise | 2026-03-02 | 2026-03-04 | 5,101 | $2.76 | $14.1K | 71,246 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-03-02 | 2026-03-04 | 4,090 | $27.51 | $112.5K | 67,156 | SEC↗ |
| Shaikhly Samira | Chief People Officer | S Sale | 2026-03-02 | 2026-03-04 | 66,363 | $28.14 | $1.87M | 793 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise deriv | 2026-02-18 | 2026-02-20 | 4,000 | — | $0 | 88,911 | SEC↗ |
| Bhatt Elizabeth | President and COO | M Exercise | 2026-02-18 | 2026-02-20 | 4,000 | $6.81 | $27.2K | 178,209 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-02-18 | 2026-02-20 | 2,200 | $28.46 | $62.6K | 176,009 | SEC↗ |
| Bhatt Elizabeth | President and COO | S Sale | 2026-02-18 | 2026-02-20 | 1,800 | $29.58 | $53.2K | 174,209 | SEC↗ |
| Wilson Mark Andrew | Chief Legal Officer | A Award deriv | 2026-02-06 | 2026-02-10 | 165,000 | — | $0 | 165,000 | SEC↗ |
| Finer Jeffrey | Chief Executive Officer | A Award deriv | 2026-02-06 | 2026-02-10 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Bhatt Elizabeth | President and COO | A Award deriv | 2026-02-06 | 2026-02-10 | 155,000 | — | $0 | 155,000 | SEC↗ |
| Kim Jae B. | Chief Medical Officer | A Award deriv | 2026-02-06 | 2026-02-10 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | A Award deriv | 2026-02-06 | 2026-02-10 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Shaikhly Samira | Chief People Officer | A Award deriv | 2026-02-06 | 2026-02-10 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | A Award deriv | 2026-02-06 | 2026-02-10 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | A Award deriv | 2026-02-06 | 2026-02-10 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | S Sale | 2025-11-10 | 2025-11-13 | 3,501 | $18.06 | $63.2K | 92,911 | SEC↗ |
| Gottesdiener Keith Michael | Director | A Award deriv | 2025-09-25 | 2025-09-29 | 33,246 | — | $0 | 33,246 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | M Exercise deriv | 2025-08-18 | 2025-08-19 | 10,452 | — | $0 | 10,453 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | M Exercise deriv | 2025-08-18 | 2025-08-19 | 7,621 | — | $0 | 33,027 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | M Exercise deriv | 2025-08-18 | 2025-08-19 | 4,935 | — | $0 | 9,001 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | M Exercise | 2025-08-18 | 2025-08-19 | 4,935 | $2.76 | $13.6K | 15,387 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | M Exercise | 2025-08-18 | 2025-08-19 | 7,621 | $6.81 | $51.9K | 23,008 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | M Exercise | 2025-08-18 | 2025-08-19 | 10,452 | $2.76 | $28.8K | 10,452 | SEC↗ |
| Klein Uwe | SVP, Biological Sciences | A Award deriv | 2025-08-07 | 2025-08-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Long Daniel D. | SVP, Drug Discovery | A Award deriv | 2025-08-07 | 2025-08-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Finer Jeffrey | Chief Executive Officer | A Award deriv | 2025-08-07 | 2025-08-11 | 210,000 | — | $0 | 210,000 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | A Award deriv | 2025-08-07 | 2025-08-11 | 37,500 | — | $0 | 37,500 | SEC↗ |
| Kim Jae B. | Chief Medical Officer | A Award deriv | 2025-08-07 | 2025-08-11 | 55,000 | — | $0 | 55,000 | SEC↗ |
| Bhatt Elizabeth | President and COO | A Award deriv | 2025-08-07 | 2025-08-11 | 95,000 | — | $0 | 95,000 | SEC↗ |
| Shaikhly Samira | Chief People Officer | A Award deriv | 2025-08-07 | 2025-08-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Ezekowitz Alan | Director | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| Bassan Abraham | Director | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| Simson Jake | Director | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| Coulie Bernard | Director | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| Tong Jeffrey K | Director | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| Sharp Shalini | Director | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| RA Capital Healthcare Fund LP | Director, 10% Owner | A Award deriv | 2025-06-17 | 2025-06-20 | 16,623 | — | $0 | 16,623 | SEC↗ |
| Finer Jeffrey | CEO and President | M Exercise deriv | 2025-04-03 | 2025-04-04 | 5,000 | — | $0 | 397,212 | SEC↗ |
| Finer Jeffrey | CEO and President | M Exercise | 2025-04-03 | 2025-04-04 | 5,000 | $2.76 | $13.8K | 826,907 | SEC↗ |
| Finer Jeffrey | CEO and President | M Exercise deriv | 2025-04-02 | 2025-04-04 | 50,000 | — | $0 | 402,212 | SEC↗ |
| Finer Jeffrey | CEO and President | M Exercise | 2025-04-02 | 2025-04-04 | 50,000 | $2.76 | $138.0K | 821,907 | SEC↗ |
| Ezekowitz Alan | Director | P Buy | 2025-03-07 | 2025-03-10 | 13,319 | $6.93 | $92.3K | 117,420 | SEC↗ |
| Ezekowitz Alan | Director | P Buy | 2025-03-06 | 2025-03-06 | 41,355 | $6.00 | $248.1K | 104,101 | SEC↗ |
| Ezekowitz Alan | Director | P Buy | 2025-03-05 | 2025-03-06 | 37,835 | $5.82 | $220.2K | 62,746 | SEC↗ |
| Ezekowitz Alan | Director | P Buy | 2025-03-04 | 2025-03-06 | 7,491 | $6.35 | $47.6K | 24,911 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | P Buy | 2025-02-27 | 2025-02-27 | 3,718 | $5.85 | $21.8K | 40,000 | SEC↗ |
| Finer Jeffrey | CEO and President | P Buy | 2025-02-27 | 2025-02-27 | 3,000 | $5.80 | $17.4K | 771,907 | SEC↗ |
| Finer Jeffrey | CEO and President | P Buy | 2025-02-26 | 2025-02-27 | 4,000 | $5.70 | $22.8K | 768,907 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | P Buy | 2025-02-25 | 2025-02-27 | 6,282 | $5.59 | $35.1K | 36,282 | SEC↗ |
| Finer Jeffrey | CEO and President | P Buy | 2025-02-25 | 2025-02-27 | 10,000 | $5.68 | $56.8K | 764,907 | SEC↗ |
| Third Rock Ventures GP V, LP | 10% Owner | P Buy | 2025-02-24 | 2025-02-26 | 18,861 | $6.00 | $113.2K | 4,211,659 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | P Buy | 2025-02-21 | 2025-02-21 | 5,000 | $5.85 | $29.3K | 30,000 | SEC↗ |
| Third Rock Ventures GP V, LP | 10% Owner | P Buy | 2025-02-21 | 2025-02-24 | 427,668 | $5.94 | $2.54M | 4,192,798 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | P Buy | 2025-02-20 | 2025-02-21 | 14,500 | $5.88 | $85.3K | 25,000 | SEC↗ |
| Third Rock Ventures GP V, LP | 10% Owner | P Buy | 2025-02-20 | 2025-02-24 | 612,674 | $5.92 | $3.63M | 3,765,130 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | P Buy | 2025-02-19 | 2025-02-21 | 10,500 | $5.51 | $57.9K | 10,500 | SEC↗ |
| Labrucherie Gil M | Chief Financial Officer | A Award deriv | 2025-02-07 | 2025-02-07 | 222,000 | — | $0 | 222,000 | SEC↗ |
| TRV GP V, LLC | 10% Owner | C Conversion deriv | 2024-10-28 | 2024-10-28 | 24,737,017 | — | $0 | 0 | SEC↗ |
| TRV GP V, LLC | 10% Owner | C Conversion deriv | 2024-10-28 | 2024-10-28 | 41,250,000 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | C Conversion deriv | 2024-10-28 | 2024-10-30 | 14,598,896 | — | $0 | 0 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | C Conversion deriv | 2024-10-28 | 2024-10-30 | 9,732,596 | — | $0 | 0 | SEC↗ |
| TRV GP V, LLC | 10% Owner | P Buy | 2024-10-28 | 2024-10-28 | 279,500 | $18.00 | $5.03M | 3,152,456 | SEC↗ |
| TRV GP V, LLC | 10% Owner | C Conversion | 2024-10-28 | 2024-10-28 | 2,872,956 | — | $0 | 2,872,956 | SEC↗ |
| TRV GP V, LLC | 10% Owner | P Buy | 2024-10-28 | 2024-10-28 | 370,500 | $18.00 | $6.67M | 6,215,591 | SEC↗ |
| TRV GP V, LLC | 10% Owner | C Conversion | 2024-10-28 | 2024-10-28 | 4,790,773 | — | $0 | 5,845,091 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | P Buy | 2024-10-28 | 2024-10-30 | 341,600 | $18.00 | $6.15M | 1,471,943 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | P Buy | 2024-10-28 | 2024-10-30 | 3,828,400 | $18.00 | $68.91M | 5,523,915 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | C Conversion | 2024-10-28 | 2024-10-30 | 1,130,343 | — | $0 | 1,130,343 | SEC↗ |
| Shah Rajeev M. | Director, 10% Owner | C Conversion | 2024-10-28 | 2024-10-30 | 1,695,515 | — | $0 | 1,695,515 | SEC↗ |